1. Home
  2. BCAX
  3. BCAX News

Latest BICARA THERAPEUTICS INC (BCAX) News on June 3, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
BCAX

GlobeNewswire

2 days ago

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer
BCAX

Clinical Trials Arena

5 days ago

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
BCAX

Insider Monkey

6 days ago

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
BCAX

Insider Monkey

8 days ago

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

BCAX

MT Newswires

10 days ago

Sector Update: Health Care Stocks Decline Late Afternoon

BCAX

MT Newswires

10 days ago

Bicara Therapeutics Shares Fall After Cancer Drug Trial Fails to Reach Survival Benchmark

BCAX

MT Newswires

10 days ago

Top Midday Decliners

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
BCAX

Investor's Business Daily

11 days ago

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

BCAX

MT Newswires

11 days ago

Top Premarket Decliners

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
BCAX

GlobeNewswire

11 days ago

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
BCAX

GlobeNewswire

21 days ago

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
BCAX

GlobeNewswire

a month ago

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

BCAX

MT Newswires

a month ago

Wedbush Trims Price Target on Bicara Therapeutics to $30 From $31, Keeps Outperform Rating

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BCAX

GlobeNewswire

a month ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BCAX

MT Newswires

2 months ago

Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
BCAX

GlobeNewswire

2 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BCAX

GlobeNewswire

2 months ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth
BCAX

Simply Wall St.

3 months ago

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BCAX

GlobeNewswire

3 months ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BCAX

GlobeNewswire

4 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BCAX

MT Newswires

4 months ago

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BCAX

GlobeNewswire

4 months ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia
BCAX

Clinical Trials Arena

5 months ago

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

BCAX

MT Newswires

7 months ago

Bicara Therapeutics' Q3 Loss Narrows

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
BCAX

GlobeNewswire

7 months ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BCAX

GlobeNewswire

7 months ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Opening Day: Another trio of biotech IPOs make Friday debut
BCAX

TipRanks

8 months ago

Opening Day: Another trio of biotech IPOs make Friday debut

BCAX

Investing.com

8 months ago

MBX Biosciences earns Buy rating at three investment firms

BCAX

GuruFocus.com

8 months ago

RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc
BCAX

GuruFocus.com

8 months ago

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc

FMR LLC Acquires New Stake in Bicara Therapeutics Inc
BCAX

GuruFocus.com

8 months ago

FMR LLC Acquires New Stake in Bicara Therapeutics Inc

BCAX

MT Newswires

9 months ago

Bicara Therapeutics Insider Bought Shares Worth $1,260,000, According to a Recent SEC Filing

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity
BCAX

Pharmaceutical Technology

9 months ago

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

BCAX

MT Newswires

9 months ago

MBX Biosciences Closes Upsized IPO

BCAX

MT Newswires

9 months ago

Bicara Therapeutics Closes $362 Million IPO

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BCAX

GlobeNewswire

9 months ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Share on Social Networks: